JP7730298B2 - Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用 - Google Patents

Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用

Info

Publication number
JP7730298B2
JP7730298B2 JP2021575393A JP2021575393A JP7730298B2 JP 7730298 B2 JP7730298 B2 JP 7730298B2 JP 2021575393 A JP2021575393 A JP 2021575393A JP 2021575393 A JP2021575393 A JP 2021575393A JP 7730298 B2 JP7730298 B2 JP 7730298B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537553A5 (https=
JP2022537553A (ja
Inventor
クリストファー エー． クレバノフ，
スミタ エス． チャンドラン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2022537553A publication Critical patent/JP2022537553A/ja
Publication of JP2022537553A5 publication Critical patent/JP2022537553A5/ja
Priority to JP2025004808A priority Critical patent/JP2025061710A/ja
Application granted granted Critical
Publication of JP7730298B2 publication Critical patent/JP7730298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01153—Phosphatidylinositol-4,5-bisphosphate 3-kinase (2.7.1.153), i.e. phosphoinositide 3-kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2021575393A 2019-06-20 2020-06-19 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用 Active JP7730298B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025004808A JP2025061710A (ja) 2019-06-20 2025-01-14 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864148P 2019-06-20 2019-06-20
US62/864,148 2019-06-20
PCT/US2020/038592 WO2020257553A1 (en) 2019-06-20 2020-06-19 T cell receptors targeting pik3ca mutations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025004808A Division JP2025061710A (ja) 2019-06-20 2025-01-14 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用

Publications (3)

Publication Number Publication Date
JP2022537553A JP2022537553A (ja) 2022-08-26
JP2022537553A5 JP2022537553A5 (https=) 2023-06-14
JP7730298B2 true JP7730298B2 (ja) 2025-08-27

Family

ID=74040933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575393A Active JP7730298B2 (ja) 2019-06-20 2020-06-19 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用
JP2025004808A Pending JP2025061710A (ja) 2019-06-20 2025-01-14 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025004808A Pending JP2025061710A (ja) 2019-06-20 2025-01-14 Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用

Country Status (6)

Country Link
US (1) US12492237B2 (https=)
EP (1) EP3986450A4 (https=)
JP (2) JP7730298B2 (https=)
CN (1) CN114245745A (https=)
CA (1) CA3144054A1 (https=)
WO (1) WO2020257553A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220827A1 (en) * 2023-04-21 2024-10-24 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
WO2025034618A1 (en) * 2023-08-04 2025-02-13 Vcreate, Inc. A novel t-cell receptor and uses thereof
CN117736310B (zh) * 2023-12-15 2025-03-18 重庆医科大学 一种hla-a1101限制性抗原表位肽、靶向表位肽tcr及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524372A (ja) 2014-05-29 2017-08-31 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
WO2008060510A2 (en) 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
CN102174576A (zh) 2011-01-25 2011-09-07 西北农林科技大学 一种由锌指核酸酶介导的哺乳动物内源基因定向敲除的方法和该锌指核酸酶及其表达载体
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
EP4252759B1 (en) * 2018-05-11 2025-08-06 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524372A (ja) 2014-05-29 2017-08-31 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancers，2019年02月24日，Vol.11, No.2，Article number:266, p.1-14
PNAS，2007年，Vol.104, No.13，p.5569-5574

Also Published As

Publication number Publication date
CN114245745A (zh) 2022-03-25
US12492237B2 (en) 2025-12-09
EP3986450A1 (en) 2022-04-27
EP3986450A4 (en) 2023-06-28
JP2025061710A (ja) 2025-04-11
JP2022537553A (ja) 2022-08-26
CA3144054A1 (en) 2020-12-24
WO2020257553A1 (en) 2020-12-24
US20220110976A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CN109803983B (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞，其制备方法和应用
US20240091361A1 (en) T cell receptors targeting ras mutations and uses thereof
JP2025061710A (ja) Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用
US20250313606A1 (en) T cell receptors targeting pik3ca mutations and uses thereof
CN113454115B (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
JP2017537629A (ja) Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
WO2023133540A1 (en) Il-12 affinity variants
JP2023514148A (ja) Ｃｄ２８変異を有するキメラ抗原受容体およびその使用
US20250144211A1 (en) Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
ES2983407T3 (es) Métodos para identificar receptores de linfocitos T específicos de antígeno
US20240189426A1 (en) Chimeric receptors targeting muc16 and uses thereof
HK40070453A (en) T cell receptors targeting pik3ca mutations and uses thereof
WO2025034618A1 (en) A novel t-cell receptor and uses thereof
WO2026021544A1 (zh) 表达辅助受体的细胞
US20220273714A1 (en) T-cell receptors and methods of use thereof
AU2024298426A1 (en) T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2024148369A1 (en) Targeted il-12 affinity variants
WO2025180504A1 (zh) 表达辅助受体的细胞
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia
BR112017011909B1 (pt) Receptor de antígeno quimérico (car), molécula de ácido nucleico, vetor, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar um tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250815

R150 Certificate of patent or registration of utility model

Ref document number: 7730298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150